ALLMedicine™ Retinal Detachment Center
Research & Reviews 2,741 results
https://doi.org/10.1016/j.ajo.2022.07.022
American Journal of Ophthalmology; Sothivannan A, Eshtiaghi A et. al.
Aug 7th, 2022 - To determine the relationship between time from symptom onset or presentation to repair and visual outcomes for macula-on and macula-off rhegmatogenous retinal detachment (RRD). Meta-analysis. We searched MEDLINE, EMBASE, and Cochrane Library for ...
https://emedicine.medscape.com/article/909996-treatment
Aug 4th, 2022 - Surgical Care Approximately 30% of patients with seizures do not respond to anticonvulsant medications. In these patients, conduct an appropriate evaluation to verify if they are good candidates for resective epilepsy surgery or vagal nerve stimul...
https://clinicaltrials.gov/ct2/show/NCT03011541
Aug 3rd, 2022 - Eyes with loss of vision from retinal or optic nerve conditions generally considered irreversible will be treated with a combination of injections of autologous bone marrow derived stem cells isolated from the bone marrow using standard medical an...
https://doi.org/10.1001/jamanetworkopen.2022.24892
JAMA Network Open; Muanda FT, Sood MM et. al.
Aug 3rd, 2022 - Population-based data are needed to inform the safe prescribing of fluoroquinolone antibiotics to patients with advanced chronic kidney disease (CKD). To quantify the 14-day risk of a hospital visit with nervous system and/or psychiatric disorders...
https://doi.org/10.1016/j.ajo.2022.07.017
American Journal of Ophthalmology; Ben Ghezala I, Mariet AS et. al.
Jul 31st, 2022 - To report the incidence of postoperative rhegmatogenous retinal detachment after macular surgery in France between 2006 and 2016 and identify associated factors. Nationwide population-based cohort study. All surgical procedures for an epiretinal m...
Drugs 2 results see all →
Clinicaltrials.gov 267 results
https://clinicaltrials.gov/ct2/show/NCT03011541
Aug 3rd, 2022 - Eyes with loss of vision from retinal or optic nerve conditions generally considered irreversible will be treated with a combination of injections of autologous bone marrow derived stem cells isolated from the bone marrow using standard medical an...
https://clinicaltrials.gov/ct2/show/NCT05463679
Jul 29th, 2022 - The primary efficacy endpoint of this study will be defined as the time to intervention for an arterial event (rupture, dissection, pseudoaneurysm, carotid-cavernous sinus fistula, or aneurysm, fatal or not) or mortality attributable to an arteria...
https://clinicaltrials.gov/ct2/show/NCT05331664
Jul 28th, 2022 - This is a non-inferiority, single-center, randomized, controlled, open-label clinical trial. Investigators will recruit patients that present to their clinic or emergency department with newly diagnosed mac-on or mac-off rhegmatogenous retinal det...
https://clinicaltrials.gov/ct2/show/NCT05478967
Jul 28th, 2022 - The enrolled eyes were randomly assigned according to the Central Randomization System with a ratio of 1∶1 to IVA group and control group. Patients in IVA group received an IVA (0.5 mg/0.05 ml) injection before surgery (1 to 5 days before surgery)...
https://clinicaltrials.gov/ct2/show/NCT03083431
Jul 27th, 2022 - Threshold Retinopathy of Prematurity (ROP), observed in a fraction of extremely premature infants, is characterized by retinal vessel proliferation that threatens vision secondary to retinal detachment. Currently available treatments (ablative las...
News 133 results
https://www.medscape.com/viewarticle/977587
Jul 20th, 2022 - NEW YORK — Intravitreal methotrexate injections can reduce the need for reoperation after surgery for retinal detachment, even in eyes with complex pathology, researchers say. "The main goal of this study was to see if it may work in the sick diab...
https://www.medscape.com/viewarticle/977201
Jul 14th, 2022 - FRANCE — Today, close to 40% of adults in France are nearsighted. Experts say that in 2050, that number could be as high as 60%. The Institute for Medical Education and Prevention (IEMP) has launched a nationwide campaign to raise awareness about ...
https://www.medscape.com/viewarticle/972431
Apr 20th, 2022 - Regular use of certain erectile dysfunction drugs — phosphodiesterase type 5 inhibitors (PDE5 inhibitors) — may be associated with an increased risk for several ocular adverse events, according to new research. In a cohort study of 213,033 men, th...
https://www.medscape.com/viewarticle/972271
Apr 18th, 2022 - (Reuters Health) - Men who regularly used Viagra and other popular erectile dysfunction prescription drugs were more likely to suffer visual impairment, including retinal detachment and blindness, a large cohort study finds. The adjusted risks for...
https://www.medscape.com/viewarticle/972064
Apr 13th, 2022 - People who use phosphodiesterase type 5 inhibitors (PDE5Is), a class of medications most often prescribed for erectile dysfunction, may run an increased risk of vision-threatening ocular conditions, researchers say. Patients in an insurance databa...